SS-31 vs MOTS-C: two mitochondrial peptides, two different jobs

SS-31 and MOTS-C get sold together as "mitochondrial peptides," but lumping them is the most common mistake in the space. They work on different problems, through different mechanisms, and show up differently (or not at all) on your labs.

SS-31 (elamipretide) is a synthetic tetrapeptide that concentrates on the inner mitochondrial membrane and binds cardiolipin, the phospholipid that holds the electron transport chain together. By protecting cardiolipin from oxidation, it keeps the chain assembled and cuts reactive oxygen species at the source. Its job is mitochondrial quality and oxidative stress. It received FDA accelerated approval as Forzinity in September 2025 for Barth syndrome.

MOTS-C is a naturally occurring mitochondrial-derived peptide encoded in the 12S rRNA gene. It activates AMPK and behaves like an exercise mimetic, improving insulin-independent glucose uptake. Its job is metabolic: glucose, insulin sensitivity, and HbA1c.

The practical upshot is on monitoring. MOTS-C targets markers a standard panel already measures, so you can track whether it is working. SS-31 has no validated blood marker of effect, so there is currently nothing on a panel that confirms it is doing anything.

Core function: SS-31 is about mitochondrial integrity and oxidative stress. MOTS-C is about glucose metabolism and insulin sensitivity. Different problems entirely.

Mechanism: SS-31 binds and protects cardiolipin on the inner mitochondrial membrane, reducing ROS at the source. MOTS-C activates AMPK via the folate-AICAR pathway, driving GLUT4-mediated glucose uptake.

Origin: SS-31 is a fully synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2). MOTS-C is a natural 16-amino-acid peptide your own mitochondria encode.

Bloodwork visibility: MOTS-C targets fasting glucose, fasting insulin, HOMA-IR, and HbA1c, all trackable. SS-31 has no human-validated blood marker; its FDA approval rests on a muscle-strength test, not a lab value.

Human evidence: SS-31 has human trials, though mixed. It improved muscle ATP production in a single-dose study but missed primary endpoints in broader mitochondrial myopathy (MMPOWER-3) and post-MI muscle damage (EMBRACE STEMI). MOTS-C has mouse efficacy and human correlations, with no completed native-peptide efficacy trial.

Regulatory status: SS-31 is now FDA-approved (for Barth syndrome), which narrows compounding access. MOTS-C remains unapproved and faces FDA compounding review.

Best-fit athlete rationale: SS-31's angle is cardioprotection against AAS-driven mitochondrial oxidative stress (extrapolated, untested in athletes). MOTS-C's angle is metabolic insurance against insulin resistance from GH secretagogues and ageing.

Reach for MOTS-C if:

• Your concern is metabolic: insulin sensitivity, glucose control, offsetting a GH-secretagogue stack
• You want a peptide whose effect you can actually track on bloodwork (via HOMA-IR)
• You are an older athlete worried about the natural age-related decline in endogenous MOTS-C

Reach for SS-31 if:

• Your concern is oxidative stress, mitochondrial efficiency, or training recovery
• You are running heavy AAS and interested in the (unproven) cardioprotective rationale
• You accept that there is no blood marker to confirm it is working, so you are tracking subjective recovery only

On running both:

• Because they target different problems, stacking them is internally coherent, one for metabolism, one for oxidative stress
• But you are then running two compounds with thin human efficacy data and unreliable grey-market purity, doubling the sourcing risk
• Prioritise based on which problem you actually have rather than buying the marketed pair by default